Text Size

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

Gonzalez V.H., Berger B., Goldberg R., Gordon C.M., Khurana R.N., Angeles R., Shams N.


  • 2021
  • Translational vision science & technology
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Clinical development

  • Affiliations

    Valley Retina Institute, TX, McAllen, United States; Retina Research Center, TX, Austin, United States; Bay Area Retina Associates, CA, United States; MI, Jackson, United States; Northern California Retina Vitreous Associates, Mountain View, CA, United States; Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA; Santen USA, Emeryville, CA, USA; ProQR Therapeutics NV, MA, Cambridge, United States

Related Publications

Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.


Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II/III ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y, on behalf of the ORANGE study investigators


Awareness of Myopia Associated Complications and Perspectives on Myopia Management Among Parents of Children with Myopia in France and the UK

Hafizi R., Deferne N., Paudel N., Angerer A., Hsieh H.-T.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022